 SAN DIEGO, CA ACCESSWIRE July 13, 2021 Nascent Biotech, Inc. OTCQB:NBIO Nascent Biotech, Nascent, or the Company, a biotechnology company pioneering innovative medicines to overcome difficult-to-treat cancers and viral infections, and its collaboration partner, Manhattan BioSolutions together, the Partners, are pleased to announce promising new preliminary preclinical results for the COVID-19 vaccine candidate now progressing under joint development by the Partners. Under a research collaboration agreement signed in 2020, Nascent Biotech and Manhattan BioSolutions partnered to discover and develop a safe and affordable COVID-19 vaccination platform based on modifying licensed BCG vaccine technology originally developed for Tuberculosis TB, but with broader utility in protecting against infection from other types of viruses, some of which may have the potential to cause major outbreaks in humans. 